Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Augello

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Molecular and Cellular Endocrinology|July 26, 2011
The AR dependent cell cycle: mechanisms and cancer relevanceMatthew J Schiewer, Michael A Augello, Karen E Knudsen
Cancer Metastasis Reviews|January 16, 2014
AR function in promoting metastatic prostate cancerMichael A Augello, Robert B Den, Karen E Knudsen
The EMBO Journal|September 22, 2011
FOXA1: master of steroid receptor function in cancerMichael A Augello, Theresa E Hickey, Karen E Knudsen
Endocrine-Related Cancer|September 10, 2011
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancerMatthew J Schiewer, Robert Den, David T Hoang, et al.
Cancer Research|May 13, 2010
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogeneNicholas A Olshavsky, Clay E S Comstock, Matthew J Schiewer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Aberrant BAF57 signaling facilitates prometastatic phenotypesSucharitha Balasubramaniam, Clay E S Comstock, Adam Ertel, et al.
The Journal of Biological Chemistry|January 8, 2011
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor functionClay E S Comstock, Michael A Augello, Matthew J Schiewer, et al.
The Journal of Clinical Investigation|May 17, 2021
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancerDeli Liu, Michael A Augello, Ivana Grbesa, et al.
EMBO Molecular Medicine|March 20, 2015
Consequence of the tumor-associated conversion to cyclin D1bMichael A Augello, Lisa D Berman-Booty, Richard Carr, et al.
Urologic Oncology|April 30, 2022
A multidisciplinary approach to optimize primary prostate cancer biobankingPeter Y Cai, Muhammad Asad, Michael A Augello, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Molecular and Cellular Endocrinology|July 26, 2011
The AR dependent cell cycle: mechanisms and cancer relevanceMatthew J Schiewer, Michael A Augello, Karen E Knudsen
Cancer Metastasis Reviews|January 16, 2014
AR function in promoting metastatic prostate cancerMichael A Augello, Robert B Den, Karen E Knudsen
The EMBO Journal|September 22, 2011
FOXA1: master of steroid receptor function in cancerMichael A Augello, Theresa E Hickey, Karen E Knudsen
Endocrine-Related Cancer|September 10, 2011
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancerMatthew J Schiewer, Robert Den, David T Hoang, et al.
Cancer Research|May 13, 2010
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogeneNicholas A Olshavsky, Clay E S Comstock, Matthew J Schiewer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Aberrant BAF57 signaling facilitates prometastatic phenotypesSucharitha Balasubramaniam, Clay E S Comstock, Adam Ertel, et al.
The Journal of Biological Chemistry|January 8, 2011
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor functionClay E S Comstock, Michael A Augello, Matthew J Schiewer, et al.
The Journal of Clinical Investigation|May 17, 2021
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancerDeli Liu, Michael A Augello, Ivana Grbesa, et al.
EMBO Molecular Medicine|March 20, 2015
Consequence of the tumor-associated conversion to cyclin D1bMichael A Augello, Lisa D Berman-Booty, Richard Carr, et al.
Urologic Oncology|April 30, 2022
A multidisciplinary approach to optimize primary prostate cancer biobankingPeter Y Cai, Muhammad Asad, Michael A Augello, et al.
Pageof 3